{
    "abstract": "To evaluate blood pressure control during the immediate postpartum period in hypertensive women who had used methyldopa during pregnancy, comparing continuation of that drug with switching it for captopril.\nA single-blind, randomized clinical trial involving 172 postpartum women with hypertension who had previously used methyldopa during pregnancy at a minimum dose of 750\u00a0mg/day for at least one week prior to delivery. The subtypes of hypertension included were gestational hypertension, chronic hypertension, preeclampsia, superimposed preeclampsia, HELLP syndrome and eclampsia. Following delivery, the patients were randomized either to continue with methyldopa at a minimum dose of 250\u00a0mg, three times a day (methyldopa group, n\u00a0=\u00a088) or to switch to captopril at an initial dose of 25\u00a0mg, three times a day (captopril group, n\u00a0=\u00a084).\nLogistic regression was used to compare the groups regarding the potential to maintain blood pressure below 140/90\u00a0mmHg at over 50\u00a0% of measurements postpartum.\nIn the 48\u00a0h following delivery, no significant differences were found between the groups regarding blood pressure control (methyldopa 92.0% versus captopril 95.2%), side effects, postpartum depression (Edinburgh Postnatal Depression Scale) or other clinical outcomes (hypertensive peaks, time to blood pressure control, additional medication use, or maternal and neonatal complications).\nContinuation of antihypertensive treatment with methyldopa in the postpartum period yielded similar results to switching it for captopril, both with regard to the efficacy in controlling blood pressure and the safety of the treatment.",
    "authors": [
        {
            "affiliation": "Heart Institute (InCor), Teaching Hospital, School of Medicine, University of S\u00e3o Paulo, S\u00e3o Paulo, SP, Brazil; Lauro Wanderley Teaching Hospital, Jo\u00e3o Pessoa, Para\u00edba, Brazil. Electronic address: rossanapaivajp@gmail.com.",
            "firstname": "Rossana M C P",
            "initials": "RMCP",
            "lastname": "Marques"
        },
        {
            "affiliation": "Lauro Wanderley Teaching Hospital, Jo\u00e3o Pessoa, Para\u00edba, Brazil.",
            "firstname": "Sabina B",
            "initials": "SB",
            "lastname": "Maia"
        },
        {
            "affiliation": "Lauro Wanderley Teaching Hospital, Jo\u00e3o Pessoa, Para\u00edba, Brazil.",
            "firstname": "Andr\u00e9 T V",
            "initials": "ATV",
            "lastname": "Ara\u00fajo"
        },
        {
            "affiliation": "Lauro Wanderley Teaching Hospital, Jo\u00e3o Pessoa, Para\u00edba, Brazil.",
            "firstname": "Lara M C",
            "initials": "LMC",
            "lastname": "Ara\u00fajo"
        },
        {
            "affiliation": "Lauro Wanderley Teaching Hospital, Jo\u00e3o Pessoa, Para\u00edba, Brazil.",
            "firstname": "Thereza V Q",
            "initials": "TVQ",
            "lastname": "Dias"
        },
        {
            "affiliation": "Lauro Wanderley Teaching Hospital, Jo\u00e3o Pessoa, Para\u00edba, Brazil.",
            "firstname": "Gabriela T B R",
            "initials": "GTBR",
            "lastname": "Nogueira"
        },
        {
            "affiliation": "Heart Institute (InCor) do Hospital das Cl\u00ednicas da Faculdade de Medicina da Universidade de S\u00e3o Paulo, S\u00e3o Paulo, SP, Brazil.",
            "firstname": "Luiz A",
            "initials": "LA",
            "lastname": "Bortolotto"
        }
    ],
    "conclusions": "Continuation of antihypertensive treatment with methyldopa in the postpartum period yielded similar results to switching it for captopril, both with regard to the efficacy in controlling blood pressure and the safety of the treatment.",
    "copyrights": "Copyright \u00a9 2025 International Society for the Study of Hypertension in Pregnancy. Published by Elsevier B.V. All rights reserved.",
    "doi": "10.1016/j.preghy.2025.101195",
    "journal": "Pregnancy hypertension",
    "keywords": [
        "Captopril",
        "Hypertension",
        "Methyldopa",
        "Postpartum period",
        "Pregnancy-induced"
    ],
    "methods": null,
    "publication_date": "2025-01-31",
    "pubmed_id": "39884047",
    "results": "In the 48\u00a0h following delivery, no significant differences were found between the groups regarding blood pressure control (methyldopa 92.0% versus captopril 95.2%), side effects, postpartum depression (Edinburgh Postnatal Depression Scale) or other clinical outcomes (hypertensive peaks, time to blood pressure control, additional medication use, or maternal and neonatal complications).",
    "title": "Management of hypertension in the early postpartum: A randomized controlled trial.",
    "xml": "<Element 'PubmedArticle' at 0x7885063200e0>"
}